Lawrence N Shulman1, Donald A Berry2, Constance T Cirrincione2, Heather P Becker2, Edith A Perez2, Ruth O'Regan2, Silvana Martino2, Charles L Shapiro2, Charles J Schneider2, Gretchen Kimmick2, Harold J Burstein2, Larry Norton2, Hyman Muss2, Clifford A Hudis2, Eric P Winer2. 1. Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY. Lawrence_Shulman@dfci.harvard.edu. 2. Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract
PURPOSE:Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered less toxicity. PATIENTS AND METHODS: Patients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to address the noninferiority of single-agent T to AC, defined as the one-sided 95% upper-bound CI (UCB) of hazard ratio (HR) of T versus AC less than 1.30 for the primary end point of relapse-free survival (RFS). As a 2 × 2 factorial design, duration of therapy was also addressed and was previously reported. RESULTS: With 3,871 patients enrolled onto the trial, a median follow-up period of 6.1 years, and 437 RFS events, we achieved an HR of 1.26 (one sided 95% UCB, 1.48; favoring AC does not allow a conclusion of noninferiority of T with AC; UCB > 1.3). With 266 patient deaths, the HR for overall survival (OS) was 1.27 favoring AC (UCB, 1.56). The estimated absolute advantage of AC at 5 years is 3% for RFS (91 v 88%) and 1% for OS (95 v 94%). All nine treatment-related deaths were patients receiving AC and are included in the analyses of both RFS and OS. Hematologic toxicity was more common in patients treated with AC, and neuropathy was more common in patients treated with T. CONCLUSION: This trial did not show noninferiority of T to AC, a conclusion that is unlikely to change with additional events and follow-up. T was less toxic than AC.
RCT Entities:
PURPOSE: Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered less toxicity. PATIENTS AND METHODS: Patients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to address the noninferiority of single-agent T to AC, defined as the one-sided 95% upper-bound CI (UCB) of hazard ratio (HR) of T versus AC less than 1.30 for the primary end point of relapse-free survival (RFS). As a 2 × 2 factorial design, duration of therapy was also addressed and was previously reported. RESULTS: With 3,871 patients enrolled onto the trial, a median follow-up period of 6.1 years, and 437 RFS events, we achieved an HR of 1.26 (one sided 95% UCB, 1.48; favoring AC does not allow a conclusion of noninferiority of T with AC; UCB > 1.3). With 266 patientdeaths, the HR for overall survival (OS) was 1.27 favoring AC (UCB, 1.56). The estimated absolute advantage of AC at 5 years is 3% for RFS (91 v 88%) and 1% for OS (95 v 94%). All nine treatment-related deaths were patients receiving AC and are included in the analyses of both RFS and OS. Hematologic toxicity was more common in patients treated with AC, and neuropathy was more common in patients treated with T. CONCLUSION: This trial did not show noninferiority of T to AC, a conclusion that is unlikely to change with additional events and follow-up. T was less toxic than AC.
Authors: Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer Journal: N Engl J Med Date: 2005-10-27 Impact factor: 91.245
Authors: Lawrence N Shulman; Constance T Cirrincione; Donald A Berry; Heather P Becker; Edith A Perez; Ruth O'Regan; Silvana Martino; James N Atkins; Erica Mayer; Charles J Schneider; Gretchen Kimmick; Larry Norton; Hyman Muss; Eric P Winer; Clifford Hudis Journal: J Clin Oncol Date: 2012-07-23 Impact factor: 44.544
Authors: A U Buzdar; S E Singletary; R L Theriault; D J Booser; V Valero; N Ibrahim; T L Smith; L Asmar; D Frye; N Manuel; S W Kau; M McNeese; E Strom; K Hunt; F Ames; G N Hortobagyi Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: B Fisher; A M Brown; N V Dimitrov; R Poisson; C Redmond; R G Margolese; D Bowman; N Wolmark; D L Wickerham; C G Kardinal Journal: J Clin Oncol Date: 1990-09 Impact factor: 44.544
Authors: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-02-13 Impact factor: 44.544
Authors: George W Sledge; Donna Neuberg; Patricia Bernardo; James N Ingle; Silvana Martino; Eric K Rowinsky; William C Wood Journal: J Clin Oncol Date: 2003-02-15 Impact factor: 44.544
Authors: Eleftherios P Mamounas; John Bryant; Barry Lembersky; Louis Fehrenbacher; Scot M Sedlacek; Bernard Fisher; D Lawrence Wickerham; Greg Yothers; Atilla Soran; Norman Wolmark Journal: J Clin Oncol Date: 2005-05-16 Impact factor: 44.544
Authors: Lori J Goldstein; Anne O'Neill; Joseph A Sparano; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson Journal: J Clin Oncol Date: 2008-08-04 Impact factor: 44.544
Authors: Clifford A Hudis; William E Barlow; Joseph P Costantino; Robert J Gray; Kathleen I Pritchard; Judith-Anne W Chapman; Joseph A Sparano; Sally Hunsberger; Rebecca A Enos; Richard D Gelber; Jo Anne Zujewski Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Lara E Sucheston-Campbell; Alyssa I Clay-Gilmour; William E Barlow; G Thomas Budd; Daniel O Stram; Christopher A Haiman; Xin Sheng; Li Yan; Gary Zirpoli; Song Yao; Chen Jiang; Kouros Owzar; Dawn Hershman; Kathy S Albain; Daniel F Hayes; Halle C Moore; Timothy J Hobday; James A Stewart; Abbas Rizvi; Claudine Isaacs; Muhammad Salim; Jule R Gralow; Gabriel N Hortobagyi; Robert B Livingston; Deanna L Kroetz; Christine B Ambrosone Journal: Pharmacogenet Genomics Date: 2018-02 Impact factor: 2.089
Authors: Katherina C Chua; Chenling Xiong; Carol Ho; Taisei Mushiroda; Chen Jiang; Flora Mulkey; Dongbing Lai; Bryan P Schneider; Sara R Rashkin; John S Witte; Paula N Friedman; Mark J Ratain; Howard L McLeod; Hope S Rugo; Lawrence N Shulman; Michiaki Kubo; Kouros Owzar; Deanna L Kroetz Journal: Clin Pharmacol Ther Date: 2020-08-02 Impact factor: 6.875
Authors: Rachel A Freedman; Jared C Foster; Drew K Seisler; Jacqueline M Lafky; Hyman B Muss; Harvey J Cohen; Jeanne Mandelblatt; Eric P Winer; Clifford A Hudis; Ann H Partridge; Lisa A Carey; Constance Cirrincione; Alvaro Moreno-Aspitia; Gretchen Kimmick; Aminah Jatoi; Arti Hurria Journal: J Clin Oncol Date: 2016-12-19 Impact factor: 44.544
Authors: Melina L Willson; Lucinda Burke; Thomas Ferguson; Davina Ghersi; Anna K Nowak; Nicholas Wilcken Journal: Cochrane Database Syst Rev Date: 2019-09-02